Inclusion Criteria:

- Patients diagnosed with histologically or cytologically proven, CD 20+, diffuse large
B-cell lymphoma,

- Relapse after first or second CR, PR or less than PR to first-line treatment for the
rituximab-naïve patients, OR relapse after first or second CR with a minimum delay of
12 months between the last rituximab infusion and the inclusion for the
rituximab-experienced patients

- Aged 18 - 75 years

- Not eligible for autologous transplantation

- Previously treated with chemotherapy containing anthracycline, with or without
rituximab

- ECOG performance status 0 to 2

- With a minimum life expectancy of 3 months

- Having signed informed consent form prior to enrollment

Exclusion Criteria:

- Burkitt's, mantle cell, T-cell lymphomas

- CD 20-negative lymphoma

- HIV or HBV related disease

- Central nervous system or meningeal involvement by the lymphoma

- Not previously treated with anthracycline-containing regimens

- Contraindication to any drug contained in the R-GEMOX chemotherapy regimen

- Any serious active disease or co-morbid medical condition (according to the
investigator's decision),

- Poor renal function (creatinine level > 150micromol/l), poor hepatic function (total
bilirubin level > 30mmol/l, transaminases > 2.5 maximum normal level) unless these
abnormalities are related to the lymphoma

- Poor bone marrow reserve as defined by neutrophils < 1.5 G/l or platelets < 100 G/l,
unless related to bone marrow infiltration

- Any history of cancer during the last 5 years, with the exception of non-melanoma
skin tumors or stage 0 (in situ) cervical carcinoma

- Treatment with any investigational drug within 30 days before planned first cycle of
chemotherapy and during the study

- Any radiotherapy during the four weeks before inclusion

- Pregnant or lactating woman

- Adult patient unable to give informed consent because of intellectual impairment.